Laboratory Corporation of America, a healthcare diagnostics, is the first United States-based laboratory to offer Epi proColon, a blood-based test for colorectal cancer screening.
Here are four key notes:
1. Epigenomics developed the test, and it is available in the U.S. through a joint commercialization agreement with Polymedco.
2. The Epi proColon test detects Epigenomics proprietary Septin9 DNA methylation biomarker for colorectal cancer in cell-free DNA circulating in blood.
3. The test was approved by the FDA in April.
4. Epi proColon provides an alternative to stool testing or colonoscopy.